Physicians' Academy for Cardiovascular Education

Anti-inflammation heralds the future of CV medicine

10' education - Feb. 8, 2021 - Prof. Paul Ridker, MD - Boston, MA, USA

Video navigation menu

  • Residual inflammatory risk 0:42
  • Findings from the CANTOS trial 1:57
  • Findings with colchicine in patients with chronic atherosclerosis 3:11
  • Colchicine in those with ACS and acute MI  7:31
  • Anticipated guideline recommendations 11:25

Do you agree that the time has come to give colchicine to patients with stable atherosclerotic disease?

  • Yes
  • No

Educational information

This video was recorded in response to a recent publication of a subanalysis of COLCOT in Eur Heart J.

Faculty

Dr. Paul M Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women’s Hospital in Boston, MA, USA.

Disclosures

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Read our summary of a subanalysis of COLCOT

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: